GoodRx Q3 2022 revenue of $187.3M beats guidance; adjusted EBITDA margin 27.8%

GoodRx Holdings, Inc.

2022-Q3 EPS reported -$0.07 revenue$582,445,000

Total revenue $187.3M exceeded previously announced guidance; net loss $41.7M (22.3% margin) with $29M stock-based comp.
Adjusted Net Income $29.9M (16.0% margin); Adjusted EBITDA $52.0M (27.8% margin) also beat guidance.
Subscription and pharma manufacturer solutions grew double-digits; over 865k prescribers active in last 16 months.
Net cash from operations $33.7M; exit quarter with over 7M consumers of prescription-related offerings.
Management cited grocer issue impact but noted resilient retail/PBM partnerships and focus on profitability.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

GoodRx Holdings, Inc. reported the three and nine months ended September 30, 2022 results: revenue $187.3 million, net income $41.7 million.

Period: the three and nine months ended September 30, 2022
Revenue: $187.3 million
Net income: $41.7 million
Result: reported results

Exact text from the filing

(Nasdaq: GDRX), a leading consumer-focused digital platform, has released its financial results for the third quarter of 2022. Third Quarter 2022 Highlights • Total revenue of $187.3 million, exceeding previously announced guidance • Net loss of $41.7 1 million; Net loss margin of 22.3% • Adjusted Net Income 2 of $29.9 million; Adjusted Net Income Margin 2 of 16.0% •

View on SEC.gov

Browse all earnings releases →

GoodRx Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-023201

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.